ASH 2018 | CAR T-cells for CLL: JCAR014 and ibrutinib in the R/R setting

Jordan Gauthier

Jordan Gauthier, MD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, presents the efficacy and safety results for CD19-directed JCAR014 alone or in combination with ibrutinib relapsed/refractory chronic lymphocytic leukemia (NCT01865617). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video